



Office de la Propriété

Intellectuelle

du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2552425 C 2018/02/06

(11)(21) **2 552 425**

(12) **BREVET CANADIEN**  
**CANADIAN PATENT**

(13) **C**

(86) **Date de dépôt PCT/PCT Filing Date:** 2005/02/23  
(87) **Date publication PCT/PCT Publication Date:** 2005/09/15  
(45) **Date de délivrance/Issue Date:** 2018/02/06  
(85) **Entrée phase nationale/National Entry:** 2006/07/04  
(86) **N° demande PCT/PCT Application No.:** EP 2005/001862  
(87) **N° publication PCT/PCT Publication No.:** 2005/085859  
(30) **Priorités/Priorities:** 2004/02/27 (EP04004536.1);  
2004/04/08 (EP04008586.2)

(51) **Cl.Int./Int.Cl. G01N 33/564** (2006.01)  
(72) **Inventeurs/Inventors:**  
WILD, NORBERT, DE;  
KARL, JOHANN, DE;  
GRUNERT, VEIT PETER, DE;  
ZOLG, WERNER, DE  
(73) **Propriétaire/Owner:**  
F. HOFFMANN-LA ROCHE AG, CH  
(74) **Agent:** BORDEN LADNER GERVAIS LLP

(54) **Titre : METHODE PERMETTANT D'EVALUER LA POLYARTHRITE RHUMATOIDE EN MESURANT LE TAUX DE FACTEUR RHUMATOIDE ET D'INTERLEUKINE 6**  
(54) **Title: METHOD OF ASSESSING RHEUMATOID ARTHRITIS BY MEASURING RHEUMATOID FACTOR AND INTERLEUKIN-6**

**(57) Abrégé/Abstract:**

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of RF and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with RF and interleukin-6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising RF and interleukin-6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number  
**WO 2005/085859 A1**

(51) International Patent Classification<sup>7</sup>: **G01N 33/564**

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:  
PCT/EP2005/001862

(22) International Filing Date: 23 February 2005 (23.02.2005)

(25) Filing Language: English

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

(30) Priority Data:  
04004536.1 27 February 2004 (27.02.2004) EP  
04008586.2 8 April 2004 (08.04.2004) EP

**Declarations under Rule 4.17:**

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) **Applicant (for DE only): ROCHE DIAGNOSTICS GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).

(71) **Applicant (for all designated States except DE, US): F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): WILD, Norbert** [DE/DE]; Unterfeldweg 2, 82538 Geretsried/Gelting (DE). **KARL, Johann** [DE/DE]; Bert-Schratzlseer-Strasse 7, 82380 Peissenberg (DE). **GRUNERT, Veit, Peter** [DE/DE]; Barer Strasse 58, 80799 Muenchen (DE). **ZOLG, Werner** [DE/DE]; Sportplatzweg 4a, 82362 Weilheim-Unterhausen (DE).

(74) **Common Representative: ROCHE DIAGNOSTICS GMBH**; c/o Dr. Werner Naser, 82377 Penzberg (DE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

**WO 2005/085859 A1**

(54) **Title:** METHOD OF ASSESSING RHEUMATOID ARTHRITIS BY MEASURING RHEUMATOID FACTOR AND INTERLEUKIN-6

(57) **Abstract:** The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of RF and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with RF and interleukin-6 and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising RF and interleukin-6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

## Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of 5 rheumatoid factor (=RF) and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with RF and interleukin-6 and be correlated to the absence or presence of RA. The invention also relates to the use of 10 a marker panel comprising RF and interleukin-6 in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

Rheumatoid arthritis ("RA") is a chronic, inflammatory, systemic disease that produces its most prominent manifestations in affected joints, particularly those of the hands and feet. The onset of rheumatoid arthritis can occur slowly, ranging 15 from a few weeks to a few months, or the condition can surface rapidly in an acute manner.

RA has a worldwide distribution and involves all ethnic groups. Although the disease can occur at any age, the prevalence increases with age and the peak incidence is between the fourth and sixth decade. The prevalence estimates for the 20 North American population vary from 0.3% to 1.5%. Today, over 2,500,000 individuals are diagnosed with rheumatoid arthritis in the United States alone, with some statistics indicating from 6.5 to 8 million potentially afflicted with the disease. Women are affected 2-3 times more often than men.

The early symptoms of rheumatoid arthritis are mostly joint specific such as painful 25 joints with joint swelling or tenderness, but may also include rather non-specific manifestations like stiffness, fever, subcutaneous nodules, and fatigue. Very characteristic is the symmetric involvement of joints. The joints of the hands, feet, knees and wrists are most commonly affected, with eventual involvement of the hips, elbows and shoulders. As the disease progresses, any type of motion becomes 30 very painful and difficult leading eventually to a loss of function of the involved

joints. The more severe cases of rheumatoid arthritis can lead to intense pain and joint destruction. Some 300,000 bone and joint replacement surgical procedures are performed annually in an effort to alleviate the pain and mobility loss resultant from arthritis related joint destruction.

5 The most widely used system to classify RA is the American College of Rheumatology 1987 revised criteria for the classification of RA. (Arnett, F. C., et al., Arthritis Rheum 31 (1988) 315-324). According to these criteria (known as ARA-criteria), a patient is said to have RA if the patient satisfies at least four of the following seven criteria, wherein criteria 1-4 must be present for at least six weeks:

10 1) morning stiffness for at least one hour, 2) arthritis of three or more joint areas, 3) arthritis of hand joints, 4) symmetrical arthritis, 5) rheumatoid nodules, 6) serum rheumatoid factor ("RF"), and 7) radiographic changes. These criteria have a sensitivity and specificity of approximately 90%.

15 The only biochemical marker generally accepted (see the above ARA-criteria) and aiding in the diagnosis of RA is the rheumatoid factor (RF) as detected in serum.

20 The histological changes in RA are not disease-specific but largely depend on the organ involved. The primary inflammatory joint lesion involves the synovium. The earliest changes are injury to the synovial microvasculature with occlusion of the lumen, swelling of endothelial cells, and gaps between endothelial cells, as documented by electron microscopy. This stage is usually associated with mild proliferation of the superficial lining cell layer. Two cell types constitute the synovial lining: bone marrow derived type A synoviocyte, which has macrophage features, and mesenchymal type B synoviocyte. Both cell types contribute to synovial hyperplasia, suggesting a paracrine interaction between these two cell types. This stage of inflammation is associated with congestion, oedema, and fibrin exudation. Cellular infiltration occurs in early disease and initially consists mainly of T lymphocytes. As a consequence of inflammation, the synovium becomes hypertrophic from the proliferation of blood vessels and synovial fibroblasts and from multiplication and enlargement of the synovial lining layers.

25

30 Granulation tissue extends to the cartilage and is known as pannus. The tissue actively invades and destroys the periarticular bone and cartilage at the margin between synovium and bone, known as erosive RA.

The articular manifestations of RA can be placed in two categories: reversible signs and symptoms related to inflammatory synovitis and irreversible structural damage caused by synovitis. This concept is useful not only for staging disease and determining prognosis but also for selecting medical or surgical treatment.

5 Structural damage in the typical patient usually begins sometime between the first and second year of the disease (Van der Heijde, D. M., Br J. Rheumatol. 34 (1995) 74-78). Although synovitis tends to follow a fluctuating pattern, structural damage progresses as a linear function of the amount of prior synovitis.

The aetiology of the early events in RA remains elusive. An autoimmune component is widely accepted today but other factors are still disputed. The possibility of a bacterial or viral infection has been vigorously pursued. All efforts to associate an infectious agent with RA by isolation, electron microscopy, or molecular biology have failed. It is possible that there is no single primary cause of RA and that different mechanisms may lead to the initial tissue injury and precipitate synovial inflammation.

10 Clinical signs of synovitis may be subtle and are often subjective. Warm, swollen, obviously inflamed joints are usually seen only in the most active phases of inflammatory synovitis. Cartilage loss and erosion of periarticular bone are the characteristic features of structural damage. The clinical features related to 15 structural damage are marked by progressive deterioration functionally and anatomically. Structural damage to the joint is irreversible and additive.

20 The effective treatment of rheumatoid arthritis has generally comprised a combination of medication, exercise, rest and proper joint protection therapy. The therapy for a particular patient depends on the severity of the disease and the joints 25 that are involved. Non-steroidal anti-inflammatory drugs, corticosteroids, gold salts, methotrexate and systemic immunosuppressants are widely used to reduce inflammation and joint destruction. The use of steroids and immunosuppressants, however, has significant risks and side effects both in terms of toxicity and vulnerability to potentially lethal conditions. More recently therapeutics based on 30 "biologics" have been introduced into RA-therapy. Such therapeutics, e.g., are soluble receptors or antibodies directed against TNF- $\alpha$  that significantly reduce inflammation. Though very promising, biologicals are still in limited use due to high costs.

Data from longitudinal clinical and epidemiologic studies provide guidelines for treatment. These studies emphasize 1) the need for early diagnosis, 2) identification of prognostic factors, and 3) early aggressive treatment. Earlier diagnosis and treatment, preferably within the first several months after onset of symptoms, may help prevent 5 irreversible joint damage.

Hence a need for methods, especially based on biochemical parameters, aiding in the assessment of rheumatoid arthritis exists. The present invention provides such methods and reagents for assessing the absence or presence of rheumatoid arthritis *in vitro*. The methods will also aid in monitoring the efficacy of treatment in patients 10 suffering from RA.

The present invention is directed to a method for assessing rheumatoid arthritis *in vitro* by biochemical markers, comprising measuring in a sample the concentration of RF and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis.

15 In particular, the invention provides a method for assessing the absence or presence of rheumatoid arthritis *in vitro* by biochemical markers, comprising:

- a) measuring in a sample the concentration of at least rheumatoid factor (RF) and interleukin-6 (IL-6),
- b) mathematically combining the values measured for RF and IL-6 using

20 Discriminant analysis, Kernel Methods, Nonparametric Methods, Partial Least Squares, Tree-Based Methods, Generalized Linear Models, Principal Components based Methods, Generalized Additive Models, Fuzzy Logic based Methods, Neural Networks or Genetic Algorithms based Methods, and

- c) correlating the combined value from (b) to the absence or presence of

25 rheumatoid arthritis.

The present invention also relates to the use of a marker panel comprising at least RF and interleukin-6 in the diagnosis of RA.

The present invention also provides a kit for performing the method according to the present invention comprising at least the reagents required to specifically measure RF

and interleukin-6, respectively, and optionally auxiliary reagents for performing the measurement.

In a first preferred embodiment the present invention relates to a method for assessing rheumatoid arthritis in vitro by biochemical markers, comprising measuring in a 5 sample the concentration of RF and interleukin-6 and correlating the concentrations determined to the absence or presence of rheumatoid arthritis.

As used herein, each of the following terms has the meaning associated with it in this section.

The articles "a" and "an" are used herein to refer to one or to more than one (i.e. to at 10 least one) of the grammatical object of the article. By way of example, "a marker" means one marker or more than one marker.

The term "marker" or "biochemical marker" as used herein refers to molecules to be used as a target for analyzing patient test samples. Examples of such molecular targets are proteins or polypeptides themselves as well as antibodies present in a sample. Proteins or polypeptides used as a marker in the present invention are contemplated to include any variants of said protein as well as fragments of said protein or said variant, in particular, immunologically detectable fragments. One of skill in the art would recognize that proteins which are released by cells or present in the extracellular matrix which become damaged, e.g., during inflammation could become degraded or cleaved into such fragments. Certain markers are synthesized in an inactive form, which may be subsequently activated by proteolysis. As the skilled artisan will appreciate, proteins or fragments thereof may also be present as part of a complex. Such complex also may be used as a marker in the sense of the present invention. Variants of a marker polypeptide are encoded by the same gene, but differ in their PI or MW, or both (e.g., as a result of alternative mRNA or pre-mRNA processing, e.g. alternative splicing or limited proteolysis) and in addition, or in the alternative, may arise from differential post-translational modification (e.g., glycosylation, acylation, and/or phosphorylation).

The term marker as indicated above according to the present invention also relates to antibodies present in a sample. In the case of RA these antibodies are autoantibodies, i.e. antibodies in a patient sample which bind to an antigen present in or on or produced by the patient's own cells.

The term "sample" as used herein refers to a biological sample obtained for the purpose of evaluation in vitro. In the methods of the present invention, the sample or patient sample preferably may comprise any body fluid. Preferred test samples include blood, serum, plasma, urine, saliva, and synovial fluid. Preferred samples are whole blood, serum, plasma or synovial fluid, with plasma or serum being most preferred.

As the skilled artisan will appreciate, any such diagnosis is made in vitro. The patient sample is discarded afterwards. The patient sample is merely used for the in vitro diagnostic method of the invention and the material of the patient sample is not transferred back into the patient's body. Typically, the sample is a liquid sample.

The term "assessing rheumatoid arthritis" is used to indicate that the method according to the present invention will (together with other variables, e.g., the criteria set forth by the ARA (see above)) aid the physician to establish his diagnosis of RA. In a preferred embodiment this assessment will relate to the presence or 5 absence of RA. As the skilled artisan will appreciate no biochemical marker is diagnostic with 100% specificity and at the same time 100% sensitivity for a given disease, rather biochemical markers are used to assess with a certain likelihood or predictive value the presence or absence of a disease. Preferably the method according to the present invention aids in assessing the presence or absence of RA.

10 As the skilled artisan will appreciate the step of correlating a marker level to the presence or absence of RA can be performed and achieved in different ways. In general a reference population is selected and a normal range established. It is no more than routine experimentation, to establish the normal range for both RF as well as interleukin-6 using an appropriate reference population. It is generally accepted that the normal range to a certain but limited extent depends on the 15 reference population in which it is established. The ideal reference population is high in number, e.g., hundreds to thousands, and matched for age, gender and optionally other variables of interest. The normal range in terms of absolute values, like a concentration given, also depends on the assay employed and the 20 standardization used in producing the assay.

The levels for RF and interleukin-6 have been measured and established with the assay procedures given in the examples section. It has to be understood that different assays may lead to different cut-off values, without departing from the scope of the present invention.

25 Preferred means of detection for RF and interleukin-6, respectively, are specific binding assays, especially immunoassays. Immunoassays are well known to the skilled artisan. Methods for carrying out such assays as well as practical applications and procedures are summarized in related textbooks. Examples of related textbooks are Tijssen, P., In: Practice and theory of enzyme immunoassays, eds. R. H. Burdon and v. P. H. Knippenberg, Elsevier, Amsterdam (1990) 221-278 and various 30 volumes of Methods in Enzymology, eds. S. P. Colowick, N. O. Caplan and S. P., Academic Press, dealing with immunological detection methods, especially volumes 70, 73, 74, 84, 92 and 121.

RF antibodies may be detected by homogeneous assays formats, e.g., by agglutination of latex particles coated with RF antigen.

Rheumatoid factors (=RF) are autoantibodies directed against the constant Fc-region of immunoglobulin G molecules (Waaler, E., *Acta Pathol. Microbiol. Scand.* 5 17 (1940) 172-188; Moore, T. L., and Dorner, R. N., *Clin Biochem.* 26 (1993) 75-84). Though RF has some limitations it is currently the only immunologic marker of rheumatoid arthritis included in the ARA-criteria. Besides of RA it is also found in other inflammatory rheumatic diseases, non-rheumatic disease and even in healthy persons aged over 60 years (Bartfeld, H., *Ann. NY Acad. Sci.* 168 (1969) 30-10 40). RF autoantibodies belong to all immunoglobulin classes and most of the assays used today do not differentiate between the isotypes IgM, IgG and IgA. These RF-assays, also termed total-RF assays, determine mostly IgM but also cover IgG or IgA to some degree depending on the assay format and the supplier (Bas, S., et al., *Ann. Rheum. Dis.* 61 (2002) 505-510). More recently the RF-isotypes IgG and IgA have 15 come into focus for the diagnosis of RA. When all three RF-isotypes are elevated the diagnostic value of the RF-assay might be improved (Swedler, W., et al., *J. Rheumatol.* 24 (1997) 1037-1044). Additionally some prognostic value has been ascribed to certain of these RF-isotypes. Especially, a high concentration of IgA-type RF was found to be an indicator for severe disease progression (Jorgensen, C., et al., 20 *Clin. Exp. Rheum.* 14 (1996) 301-304). In a marker combination according to the present invention the marker RF can be any form of RF-determination including total RF, single specific RF-isotypes or any combination of RF-isotypes. The preferred form of an RF marker for such marker combination is total RF.

25 Interleukin-6 (IL-6) is a 21 kDa secreted protein that has numerous biological activities that can be divided into those involved in hematopoiesis and into those involved in the activation of the innate immune response. IL-6 is an acute-phase reactant and stimulates the synthesis of a variety of proteins, including adhesion molecules. Its major function is to mediate the acute phase production of hepatic proteins, and its synthesis is induced by the cytokines IL-1 and TNF- $\alpha$ . IL-6 is 30 normally produced by macrophages and T lymphocytes. The normal serum concentration of IL-6 is < 5 pg/ml.

Whereas for RF the (auto-)antibodies as comprised in a sample are measured, for IL-6 it is the marker molecule IL-6 itself, which is detected. IL-6 for example can be measured by a competitive type or a sandwich type immunoassay. IL-6 preferably is

5 measured in a sandwich immunoassay which is essentially based on an antibody specifically binding to IL-6 which is directly or indirectly bound or capable of binding to a solid phase, an antibody specifically binding to IL-6 which is detectably labeled, and incubating these reagents under conditions allowing for binding of the anti-IL-6 antibodies to IL-6 in a sample, separating unbound detectably labeled antibody, determining the amount of labeled antibody bound via IL-6, and correlating the amount of labeled antibody bound to the concentration of IL-6 in the sample.

10 The ideal scenario for diagnosis would be a situation wherein a single event or process would cause the respective disease as, e.g., in infectious diseases. In all other cases correct diagnosis can be very difficult, especially when the etiology of the disease is not fully understood as is the case for RA. Therefore, generally various 15 clinical symptoms and biological markers are considered together for diagnosis of RA. Markers can either be determined individually or in a preferred embodiment of the invention they can be measured simultaneously using a chip or a bead based array technology.

In a method according to the present invention at least the concentrations of the biomarkers RF and IL-6 are determined and the marker combination is correlated to the absence or presence of RA.

20 As shown in the Examples section the mere combination of the two markers RF and IL-6 significantly improves the diagnostic accuracy for RA.

25 As the skilled artisan will appreciate there are many ways to use the measurements of two or more markers in order to improve the diagnostic question under investigation. In a quite simple, but nonetheless often effective approach, a positive result is assumed if a sample is positive for at least one of the markers investigated. This may e.g. the case when diagnosing an infectious disease, like AIDS. Frequently, however, the combination of markers is evaluated. Preferably the values measured for markers of a marker panel, e.g. for RF and IL-6, are mathematically combined and the combined value is correlated to the underlying diagnostic question. Marker values may be combined by any appropriate state of the art mathematical method. Well-known mathematical methods for correlating a marker combination to a disease employ methods like, Discriminant analysis (DA) (i.e. linear-, quadratic-, regularized-DA), Kernel Methods (i.e. SVM), Nonparametric 30

Methods (i.e. k-Nearest-Neighbor Classifiers), PLS (Partial Least Squares), Tree-Based Methods (i.e. Logic Regression, CART, Random Forest Methods, Boosting/Bagging Methods), Generalized Linear Models (i.e. Logistic Regression), Principal Components based Methods (i.e. SIMCA), Generalized Additive Models, 5 Fuzzy Logic based Methods, Neural Networks and Genetic Algorithms based Methods. The skilled artisan will have no problem in selecting an appropriate method to evaluate a marker combination of the present invention. Preferably the method used in correlating the marker combination of the invention e.g. to the absence or presence of RA is selected from DA (i.e. Linear-, Quadratic-, Regularized 10 Discriminant Analysis), Kernel Methods (i.e. SVM), Nonparametric Methods (i.e. k-Nearest-Neighbor Classifiers), PLS (Partial Least Squares), Tree-Based Methods (i.e. Logic Regression, CART, Random Forest Methods, Boosting Methods), or Generalized Linear Models (i.e. Logistic Regression). Details relating to these 15 statistical methods are found in the following references: Ruczinski, I., Kooperberg, C., LeBlanc, M., Logic regression, *J. of Computational and Graphical Statistics*, 12 (2003), 475-511; Friedman, J. H., Regularized Discriminant Analysis, *JASA* 84, 165-175; Hastie, Trevor, Tibshirani, Robert, Friedman, Jerome, *The Elements of Statistical Learning*, Springer Series in Statistics, 2001; Breiman, L., Friedman, J. H., Olshen, R. A., Stone, C. J., (1984) *Classification and regression trees*, California: 20 Wadsworth; Breiman, L. *Random Forests*, *Machine Learning*, 45 (2001) 5-32; Pepe, M. S., *The Statistical Evaluation of Medical Tests for Classification and Prediction*, Oxford Statistical Science Series, 28 (2003) and Duda, R. O., Hart, P. E., Stork, D. G., *Pattern Classification*, Wiley Interscience, 2nd Edition (2001).

25 It is a preferred embodiment of the invention to use an optimized multivariate cut-off for the underlying combination of biological markers and to discriminate state A from state B, e.g. diseased from healthy. In this type of analysis the markers are no longer independent but form a marker panel. It could be established that combining the measurements of RF and of IL-6 does significantly improve the diagnostic accuracy for RA as compared to either healthy controls or, as also 30 assessed, as compared to patients with osteoarthritis (OA). Especially the later finding is of great importance, because patients with OA and RA, respectively, may require quite different treatments.

35 Accuracy of a diagnostic method is best described by its receiver-operating characteristics (ROC) (see especially Zweig, M. H., and Campbell, G., *Clin. Chem.* 39 (1993) 561-577). The ROC graph is a plot of all of the sensitivity/specificity pairs

- 10 -

resulting from continuously varying the decision thresh-hold over the entire range of data observed.

5 The clinical performance of a laboratory test depends on its diagnostic accuracy, or the ability to correctly classify subjects into clinically relevant subgroups. Diagnostic accuracy measures the test's ability to correctly distinguish two different conditions of the subjects investigated. Such conditions are for example health and disease or benign versus malignant disease.

10 In each case, the ROC plot depicts the overlap between the two distributions by plotting the sensitivity versus 1 - specificity for the complete range of decision thresholds. On the y-axis is sensitivity, or the true-positive fraction [defined as (number of true-positive test results)/(number of true-positive + number of false-negative test results)]. This has also been referred to as positivity in the presence of a disease or condition. It is calculated solely from the affected subgroup. On the x-axis is the false-positive fraction, or 1 - specificity [defined as (number of false-positive results)/(number of true-negative + number of false-positive results)]. It is an index of specificity and is calculated entirely from the unaffected subgroup. 15 Because the true- and false-positive fractions are calculated entirely separately, by using the test results from two different subgroups, the ROC plot is independent of the prevalence of disease in the sample. Each point on the ROC plot represents a sensitivity/1-specificity pair corresponding to a particular decision threshold. A test with perfect discrimination (no overlap in the two distributions of results) has an ROC plot that passes through the upper left corner, where the true-positive fraction is 1.0, or 100% (perfect sensitivity), and the false-positive fraction is 0 (perfect specificity). The theoretical plot for a test with no discrimination (identical 20 distributions of results for the two groups) is a 45° diagonal line from the lower left corner to the upper right corner. Most plots fall in between these two extremes. (If the ROC plot falls completely below the 45° diagonal, this is easily remedied by reversing the criterion for "positivity" from "greater than" to "less than" or vice versa.) Qualitatively, the closer the plot is to the upper left corner, the higher the 25 overall accuracy of the test.

30

One convenient goal to quantify the diagnostic accuracy of a laboratory test is to express its performance by a single number. The most common global measure is the area under the ROC plot. By convention, this area is always  $> 0.5$  (if it is not, one can reverse the decision rule to make it so). Values range between 1.0 (perfect

5 separation of the test values of the two groups) and 0.5 (no apparent distributional difference between the two groups of test values). The area does not depend only on a particular portion of the plot such as the point closest to the diagonal or the sensitivity at 90% specificity, but on the entire plot. This is a quantitative, descriptive expression of how close the ROC plot is to the perfect one (area = 1.0).

10 In a preferred embodiment the present invention relates to a method for improving the diagnostic accuracy for rheumatoid arthritis versus healthy controls and/or patients suffering from OA by measuring in a sample the concentration of at least RF and interleukin-6 and correlating the concentrations determined to the presence or absence of rheumatoid arthritis, the improvement resulting in more patients being correctly classified as suffering from RA versus healthy controls and/or patients suffering from OA as compared to a classification based on RF alone. The RA marker panel comprising RF and IL-6 can of course also be used in assessing the severity of disease for patients suffering from RA.

15 As the skilled artisan will appreciate one or more additional biomarker may be used to further improve the assessment of RA. To illustrate this additional potential of using RF and IL-6 as the key markers of a panel of markers for assessment of RA the term "at least" has been used in the appending claims. With other words, the level measured for one or more additional marker may be combined with the 20 measurement of RF and IL-6 in the assessment of RA.

25 The one or more additional marker used together with RF and IL-6 may be considered to be part of an RA marker panel, i.e., a series of markers appropriate to further refine the assessment of RA. The total number of markers in an RA marker panel is preferably less than 20 markers, more preferred less than 15 markers, also preferred are less than 10 markers with 8 or less markers being even more preferred. Preferred are RA marker panels comprising 3, 4, 5, or 6 markers in total.

30 In a preferred embodiment the present invention thus relates to a method for assessing the absence or presence of rheumatoid arthritis in vitro by biochemical markers, comprising measuring in a sample the concentration of RF, interleukin-6 and in addition the concentration of one or more other marker and correlating the concentrations of RF, IL-6 and of the one or more additional marker to the absence or presence of rheumatoid arthritis.

It will be appreciated that the one or more other marker may be any known or future marker of RA. A marker does qualify as an RA marker if the AUC for this marker alone, when assessing the diagnostic accuracy by comparing patients with RA to healthy controls, is at least 0.65.

5 Preferably the one or more other marker is selected from the group consisting of C-reactive protein (=CRP), serum amyloid A (=SAA), S100, osteopontin, matrix metalloprotease 1 (=MMP-1), matrix metalloprotease 3 (=MMP-3), hyaluronic acid, sCD14, angiogenesis markers and products of bone, cartilage or synovium metabolism.

10 C-reactive protein (CRP) is a homopentameric  $\text{Ca}^{2+}$ -binding acute phase protein with 21 kDa subunits that is involved in host defense. CRP synthesis is induced by IL-6, and indirectly by IL-1, since IL-1 can trigger the synthesis of IL-6 by Kupffer cells in the hepatic sinusoids. The normal plasma concentration of CRP is  $< 3 \mu\text{g/ml}$  (30 nM) in 90% of the healthy population, and  $< 10 \mu\text{g/ml}$  (100 nM) in 99% of  
15 healthy individuals. Plasma CRP concentrations can, e.g. be measured by homogeneous assay formats or ELISA. C-reactive protein is a marker for underlying systemic inflammation.

20 Osteopontin (=OPN) is a secreted, highly acidic, calcium-binding, phosphorylated glycoprotein. Three isoforms are known that originate from alternative splicing which are either free or bound to the extracellular matrix. Through a RDG-motif of the 32 kDa-peptide backbone OPN can bind to integrins such as  $\alpha\beta 3$ . Though it was originally purified from bone matrix it is expressed in numerous body fluids and tissues including milk, urine, activated T-cells, macrophages, fibroblasts, smooth muscle cells, kidney tissue and some tumor cells. Its expression is  
25 stimulated in response to several cytokines, growth factors or inflammatory mediators. Increased OPN concentrations have been associated with sepsis, metastatic cancer, cerebral ischemia, atherosclerotic plaques, granuloma formation in tuberculosis and autoimmune diseases such as multiple sclerosis (Chabas, D., et al., Science 294 (2001) 1731-1735) or RA (Petrow, P. K., et al., Arthritis Rheum. 43  
30 (2000) 1597-1605).

Serum amyloid A (=SAA) is an acute phase protein of low molecular weight of 11.7 kDa. It is predominantly synthesized by the liver in response to IL-1, IL-6 or TNF- $\alpha$  stimulation and is involved in the regulation of the T-cell dependent immune

response. Upon acute events the concentration of SAA increases up to 1000-fold reaching one milligram per milliliter. It is used to monitor inflammation in diseases as divers as cystic fibrosis, renal graft refection, trauma or infections (Mozes, G. et al., J. Trauma 29 (1989) 71-74). In rheumatoid arthritis it has in certain cases been 5 used as a substitute for CRP, but, SAA is not yet as widely accepted (Chambers, R. E. et al., Ann. Rheum. Dis. 42 (1983) 665-667).

The family of matrix-metalloproteinases (=MMPs) degrades almost all components 10 of the extra-cellular matrix. Hence MMPs have been related to various types of cancer but also to inflammatory processes in RA. MMP-1 and MMP-3 are produced by fibroblasts, osteoblasts and endothelial cells upon stimulation by pro-inflammatory cytokines like IL-1 or TNF- $\alpha$ . Generally MMPs are found in the circulation as inactive pro-form and the marker MMP-1 and MMP-3, respectively, as used herein also relates to such inactive pro-form. MMP-1 and MMP-3 have 15 been detected in synovial fluid of RA-patients and the levels are responsive to anti-TNF- $\alpha$  therapy. The most preferred metalloprotease to be used in an RA marker panel according to the present invention is MMP-1. Most preferably, pro-MMP-1 is measured.

Instead of the metalloproteinases mentioned above it is also possible to used their 20 corresponding inhibitors collectively referred to as tissue inhibitors of matrix metalloproteinases (=TIMPs),, eg. MMP-1 and MMP-3 are in vivo inactivated by TIMP-1 a sialoglycoprotein of 29.5 kD that forms a 1:1 stoichiometric complex with the MMPs. The relation of TIMP-1 and TIMP-2 to the destruction of cartilage has been investigated in RA (Ishiguro, N., et al., Arthritis Rheum. 44 (2001) 2503-2511).

25 S100-proteins form a constantly increasing family of Ca<sup>2+</sup>-binding proteins that today includes more than 20 members. The physiologically relevant structure of S100-proteins is a homodimer but some can also form heterodimers with each other, e.g. S100A8 and S100A9. The intracellular functions range from regulation of protein phosphorylation, of enzyme activities, or of the dynamics of the 30 cytoskeleton to involvement in cell proliferation and differentiation. As some S100-proteins are also released from cells, extracellular functions have been described as well, e.g., neuronal survival, astrocyte proliferation, induction of apoptosis and regulation of inflammatory processes. S100A8, S100A9, the heterodimer S100A8/A9 and S100A12 have been found in inflammation with S100A8 responding to chronic

- 14 -

inflammation, while S100A9, S100A8/A9 and S100A12 are increased in acute inflammation. S100A8, S100A9, S100A8/A9 and S100A12 have been linked to different diseases with inflammatory components including some cancers, renal allograft rejection, colitis and most importantly to RA (Burmeister, G., and Gallacchi, G., *Inflammopharmacology* 3 (1995) 221-230; Foell, D., et al., *Rheumatology* 42 (2003) 1383-1389). The preferred S100 markers for use in an RA marker panel according to the present invention are S100A8, S100A9, S100A8/A9 heterodimer and S100A12.

CD14 is a membrane protein of pro-monocytes, monocytes, macrophages, and activated granulocytes where it serves as a receptor for lipopolysaccharide. It induces the secretion of cytotoxic and immunomodulating factors like reactive oxygen ( $O_2^-$ ), tumor necrosis factor (TNF- $\alpha$ ), interleukins (IL-1, IL-6 and IL-8) and platelet-activating factor (PAF). Membrane bound CD14 is shed to give soluble CD14 (=sCD14) in response to activating or differentiating factors such as IFN $\gamma$  or TNF- $\alpha$ . The physiological function of sCD14 is not yet entirely clear. Since inflammatory and immune processes are involved in RA and other autoimmune diseases, sCD14 was also investigated in such diseases. When anti-CD14 therapy was evaluated as a new therapeutic option in RA previously elevated concentrations of sCD14 rapidly decreased and synovitis was reduced (Horneff, G., et al., *Clin. Exp. Immunol.* 91 (1993) 207-213).

The glycosaminoglycan hyaluronic acid is one of the macromolecules essential for the function of a joint. It is synthesized by fibroblasts and other specialized connective tissue cells. Hyaluronic acid is involved in formation of the extracellular matrix and in cell to cell contacts. High concentrations are found in synovial fluid where it is responsible for the retention of water thereby contributing to the lubrication of joints. In rheumatoid arthritis the synthesis of hyaluronic acid is stimulated by the proinflammatory mediators IL-1 and TNF- $\alpha$  leading to increased serum/plasma levels (Sawai, T., and Uzuki, M., *Connective Tissue* 33 (2001) 253-259).

A feature of rheumatoid arthritis is the invasion of joints with proliferating synovial tissue also known as pannus. A significant part of the pannus consists of blood vessels that supplies nutrients to the growing tissue. Therefore, molecules relevant in angiogenesis have been investigated in RA also, both as RA markers but also as therapeutic targets (Brenchley, P. E. C., *Clin. Exp. Immunol.* 121 (2000) 426-429).

Amongst these the vascular endothelial growth factor (=VEGF) has been evaluated in more detail. VEGF is a secreted glycoprotein that is spliced to four different isoforms. Two of these isoforms are readily diffusible while the remaining isoforms bind tightly to heparin and are mostly found in association with heparin containing proteoglycans. VEGF acts as a chemokine on endothelial cells, monocytes and osteoblasts ultimately leading to neovascularization and increased microvascular permeability. VEGF has been detected in synovial fluid and serum of RA patients (Lee, S. S., et al., Clin. Exp. Rheumatology 19 (2001) 321-324; Ballara, S., Arthritis Rheum. 44 (2001) 2055-2064). Preferably, the marker of angiogenesis is VEGF.

The most prominent joint tissues are bone, cartilage and the synovium. Since rheumatoid arthritis is a destructive disease these tissues will be most affected. They are a likely source of potential biological markers in the field of RA. In principle these markers may come not only from the destruction of the respective tissue but also from a deregulated and/or ineffective repair process. The experienced artisan will understand that markers of bone, cartilage or synovium metabolism can originate either from synthesis or from destruction of these tissues. The various markers of bone, cartilage and/or synovium metabolism can be delineated from two different groups of proteins. They come either from the numerous types of collagen or from non-collagenous proteins. Non-collagenous proteins are often involved in the formation of the extracellular matrix. Some of these markers can be found in all three tissues in varying amounts.

Markers and products of bone and/or cartilage metabolism include both markers of bone and/or cartilage degradation as well as markers of bone and/or cartilage formation. Preferred markers derived from collagen metabolism are markers like:

1. Pyridinoline (=PYD), deoxy-pyridinoline (=DPD) and Glc-Gal-PYD: Pyridinoline (=PYD) stabilizes collagen by cross-linking the strands of the collagen triple helix. The chemical structure of PYD is very stable and can be found in serum and urine as an end product of collagen degradation (Knott, L., and Bailey, A. J., Bone 22 (1998) 181-187). It has been linked to arthritis (Kaufmann, J., et al., Rheumatology 42 (2003) 314-320). PYD monitors cartilage involvement of joint destruction since it is released from cartilage and only to some degree from bone while its close cousin deoxy-pyridinoline (=DPD) originates mostly from bone. All three markers have been linked to arthritis (Kaufmann, supra). The glycosylated

- 16 -

form Glc-Gal-PYD has mostly been found in synovial tissue (Gineyts, E., et al., Rheumatology 40 (2001) 315-323).

2. Cross-linked telopeptides: CTX-I, CTX-II, NTX-I and the LQ-epitope which are cross-linked telopeptides either from the C- or N-terminus of collagens type I or type II, respectively, and of which  $\beta$ -CTX-I is also known as  $\beta$ -CrossLaps® (Bonde, M., et al., Clin. Chem. 40 (1994) 2022-2025). Type I collagen carboxyterminal telopeptide (=ICTP) refers to a fragment and marker of type I collagen which originally has been derived from type I collagen by cyanobromide cleavage.

5

3. Linear peptides derived from collagen: The assay termed Cartilaps® measures a linear peptide that is derived from the C-terminal region of collagen type II.

10

4. Modified amino acids: Collagen comprises modified amino acids like hydroxyproline and galactosyl hydroxylysine which may be used as a marker of collagen break-down (Al-Dehaimi, A. W., et al., Clin. Chem. 45 (1999) 676-681).

15

5. Collagen neoepitopes: Col2-3/4 and CIIN are neoepitopes generated by the initial cleavage of collagen II by collagenases (Billinghurst, R. C. et al., J. Clin. Invest. 99 (1997) 1534-45).

20

6. Collagen markers considered reflecting bone formation: The N-terminal as well as the C-terminal pro-peptide of type I collagen (=PINP and PICP), respectively, are clipped from the precursor polypeptide (procollagen) during/after synthesis and considered markers of bone formation. PIICP is the corresponding pro-peptide from collagen type II, whereas PIIINP is derived from collagen III.

25

Preferably the marker of bone and/or cartilage metabolism also may be a non-collagenous marker, like: CS846, which is a chondroitin sulfate epitope created during aggrecan synthesis; cartilage oligomeric matrix protein (=COMP) that has bridging functions in cartilage (Saxne, T., and Heinegard, D., Br. J. Rheumatol. 31 (1992) 583-591); cartilage intermediate layer protein (=CILP), which is a matrix protein of cartilage (Lorenzo, P., et al., J. Biol. Chem. 273 (1998) 23463-23468); cartilage matrix proteins 1 – 3 also known as matrilins; chondromodulins that act as signaling molecules in cartilage (Suzuki, F., Connect. Tissue Res. 35 (1996) 303-307); cartilage derived retinoic acid-sensitive protein (=CD-RAP) or MIA, which has a yet to be defined function in chondrocyte modulation (Müller-Ladner, U., et

30

- 17 -

al., *Rheumatology* 38 (1999) 148-154); osteocalcin, which is synthesized by osteoblasts, belongs to the major non-collagen matrix protein of bone and is used to monitor bone turnover (Gundberg, C. M., et al., *J. Clin. Ligand Assay* 21 (1998) 128-138); and the bone sialoproteins, which are major non-collagen matrix proteins of bone, such as bone sialoprotein II, now known as bone sialoprotein, which e.g., has been evaluated as marker for bone turn-over (Saxne, T., et al., *Arthritis Rheum.* 38 (1995) 82-90).

Products of metabolism within the synovium which may be used as a marker in assessing RA include: CTX-III, which is a telopeptide derived from collagen type III, YKL40 the later being a chitinase 3 like protein of the extracellular matrix (Johansen, J. S., et al., *Scand. J. Rheumatol.* 30 (2001) 297-304), and aggrecan, which is a building block of proteoglycans as well as its degradation product keratan sulfate.

Preferably the RA marker panel comprises at least three markers, wherein RF, IL-6 and a third marker selected from the group consisting of CRP, SAA, S100, osteopontin, RF, pro-MMP-1, MMP-3, hyaluronic acid, and a product of collagen metabolism are contained.

In the assessment of RA a marker panel comprising RF, IL-6 and S100, especially, S100A12 is preferred.

Also preferred is a marker panel comprising RF, IL-6 and pro-MMP-1.

As mentioned further above (see ARA criteria) – despite of some limitations - the rheumatoid factor (RF) currently is the only biochemical marker generally accepted to aid in establishing the diagnosis of RA. It is clearly expected that the marker combination of the present invention will significantly improve the diagnosis of RA and will supplement or might be even finally replace the biochemical assessment of RA based on an RF assay alone. The use of a marker panel comprising at least RF and interleukin-6 in the diagnosis of RA therefore represents a further preferred embodiment of the present invention.

As the skilled artisan will appreciate one or more additional marker may be used to further improve the diagnostic accuracy, or, where required increase the diagnostic sensitivity at the expense of specificity or vice versa. In some diagnostic areas, e.g.,

in the detection of an HIV-infection sensitivity is of utmost importance. The high sensitivity required may be achieved at the expense of specificity, leading to an increased number of false positive cases. In other cases, e.g. as a simple example, when assessing blood group antigens, specificity is of paramount importance.

5 A further preferred embodiment relates to the use of a marker panel in the diagnosis of RA the panel comprising RF, interleukin-6 and at least one additional marker selected from the group consisting of CRP, SAA, S100, osteopontin, RF, pro-MMP-1, MMP-3, hyaluronic acid, sCD14, angiogenesis markers and products of bone, cartilage or synovium metabolism.

10 The method according to the present invention will also be of great use in assessing the severity of RA. The higher the level of RF and/or the higher the level of IL-6 the more severe is the disease. With the marker combination or marker panels now at hand it will be no more than routine experimentation to develop e.g., disease scores as an indicator for severity of disease. The method according to the present 15 invention thus is preferably also used to assess the severity of disease.

20 The method of the present invention will also be of great help in monitoring the course of disease. This is most easily achieved by measuring in a patient sample RF and IL-6 as well as optionally additional markers at various points in time and comparing the absolute and/or the relative levels of the markers at these different time points. It thus is further preferred to use the method according to the present invention to monitor the course of disease in a patient with RA.

25 It is also recognized that the present invention will be of great help in assessing the efficacy of any treatment for RA. The efficacy of treatment will be reflected by changes in the marker level. If a treatment has the desired effect at least one of the two marker levels of RF or IL-6 will decrease. The method according to the present invention thus preferably is also used to assess the efficacy of treatment. The same phenomenon, i.e. a reduction in marker level of at least one of RF or IL-6 can easily be applied for selection of the right drug as well as the most appropriate dosing of drugs in RA. The use of a method of this invention in selection of the right drug 30 and/or the most appropriate dosing is also preferred.

- 19 -

The method of the present invention will also enable the selection and identification of new drugs in the field of RA. This application represents a further preferred embodiment.

5 It will also be a great advantage that sub-groups of patients can now be identified for and in clinical studies which differ in their level of RF and IL-6 and to correlate this difference in marker level to the efficacy of the drug under investigation.

10 The present invention also relates to a kit for performing the method of this invention comprising the reagents required to specifically measure RF and interleukin-6, respectively. The kit may optionally comprise auxiliary reagents for performing the measurement of both RF and IL-6.

The following examples, references and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the invention.

15 **Description of the Figures**

“RD-Score” in all Figures stands for “regularized discriminant score, i.e., the score obtained by applying Regularized Discriminant Analysis; “AUC” in all Figures stands for “area under the curve”:

20 Figure 1 ROC-analysis of patients diagnosed with RA versus controls incl. OA using log RF alone.

Figure 2 ROC-analysis of patients diagnosed with RA versus controls incl. OA using the combination of log total RF and log IL-6.

25 Figure 3 ROC-analysis of patients diagnosed with RA versus controls incl. OA using the combination of log total RF, log IL-6, and log pro-MMP-1.

- 20 -

Example 1

Study population

Samples derived from 389 highly characterized RA patients with maximum disease duration of 15 years were collected in five European centers with a follow-up of two years. All individuals were diagnosed as RA-patients according to the ARA-criteria and had a functional status of  $\leq$  III as classified by the ARA classification criteria (Hochberg, M. C., et al., Arthritis Rheum. 35 (1992) 498-502). All patients were documented with an extensive case report form (=CRF). The CRF included the Health Assessment Questionnaire, the SF36 Questionnaire, swollen and tender joint count, the Larsen Score, laboratory parameters, clinical history of relevant surgery, medication, co-morbidities and medication for co-morbidities. X-rays were taken every year following a standardized procedure. Only baseline samples obtained from the subjects included in this study were included in the present analysis.

Samples derived from 624 control subjects were collected as well. From these controls only RA-positive subjects but not other forms of arthritis were excluded. 200 samples were drawn from this cohort to age-match the RA-samples of the study. Since the focus of the study was to discriminate RA not only from healthy subjects but also from other joint diseases, 190 patients with either tibiofemoral or patellofemoral OA of the knee were added as disease controls. For these OA patients clinical and laboratory parameters were determined and radiographic Kellgren & Lawrence Score was calculated (Kellgren, J. H., and Lawrence, J. S., Ann. Rheum. Dis. 16 (1957) 494-501).

Demographic data for the study population are given in Table 1.

Table 1:  
Patient collectives

Collective	N	Age	Gender (f/m/?)
RA	389	59.1 (16–87)	256/132/1
Controls incl. OA	390	60.6 (38–92)	195/195/0

**Example 2****Markers measured**

Table 2 presents a selection of the assays used and gives the test format as well as the suppliers of the assays. Most of the assays were manual microtiter plate format (=MTP) ELISAs. RF and CRP were determined in a homogeneous test format on an automatic Hitachi analyzer. Marker concentrations were determined in serum samples with these commercially available assays for patients as well as for controls.

**Table 2:**  
**Assays and Suppliers**

Biomarker	Assay type / format	Source
CRP	Homogenous assay, Hitachi	Roche Diagnostics, Mannheim (FRG)
Hyaluronic acid	Sandwich ELISA, MTP	Chugai, Tokyo (J)
IL-6	Sandwich ELISA, MTP	Roche Diagnostics, Mannheim (FRG)
Pro-MMP1	Sandwich ELISA, MTP	The binding site, Birmingham (UK)
RF	Homogenous assay, Hitachi	Roche Diagnostics, Mannheim (FRG)
SAA	Sandwich ELISA, MTP	Biosource, Nivelles (B)

10

**Example 3****Statistical evaluation**

The patient cohorts were randomly split in a training set (app. 67 %) and in a test set (app. 33 %). On the training set a classification algorithm was developed and on the independent test set the algorithm was validated. As can be seen in Table 3 the respective sets were closely matched in size as well as in age.

15

Table 3:  
Age distribution of collectives

Group	study	N	mean	Max	q3	median	q1	Min
Training	RA	259	58.7	87	68	59	51	23
Training	Controls incl. OA	261	60.2	92	69	60	51	42
Test	RA	130	59.8	83	68	61	52	16
Test	Controls incl. OA	129	61.3	84	70	63	52	38

5 The classification algorithms were generated with the Regularized Discriminant Analysis (RDA), which is a generalization of the common Discriminant Analysis, i.e. Quadratic- and Linear Discriminant Analysis (McLachlan, G. J., Discriminant Analysis and Statistical Pattern Recognition, Wiley Series in probability and mathematical statistics, 1992). In the RDA alternatives to the usual maximum likelihood (plug-in) estimates for the covariance matrices are used. These 10 alternatives are characterized by two parameters ( $\lambda, \gamma$ ), the values of which are customized to individual situations by jointly minimizing a sample-based estimate of future misclassification risk (Friedman, J. H., Regularized Discriminant Analysis, J. of the American Statistical Association 84 (1989) 165-175). As an alternative method Support Vector Machines algorithms (Hastie, Trevor, Tibshirani, Robert, 15 Friedman, Jerome, The Elements of Statistical Learning, Springer Series in Statistics, 2001) can be fitted with comparable classification results.

20 The marker panels were stepwise constructed starting from the best single marker for the classification problem and ending when the total classification error does not change remarkable any more. In order to gain centralized distributions every single marker was transformed with the natural logarithmic function. 10-fold cross validation was used on the training set to get robust estimates of the total error (sensitivity, specificity). Once the marker panel was defined, it was validated without any further adjustment with an independent test set.

25 Example 4  
Identification of a marker panel for the diagnosis of RA

Table 4 presents the classification results of patients diagnosed with RA versus controls incl. OA on the training set. The first marker selected was RF, the second one IL-6 and the third and last one was pro-MMP-1 then the algorithm stopped. As

a reference the classification results for total RF are presented, which as mentioned above, is currently the only biochemical marker forming part of the ARA-criteria.

The aim of the current invention was to improve the correct diagnosis of RA versus controls including OA. The diagnostic value of the identified marker panel is best reflected in Table 4 by the total error of the classification. RF, currently the single biological marker included in the ARA-criteria, gives a total error of 0.184. The preferred combination of RF and IL-6 significantly improves the classification with a total error of 0.154. Adding a third marker finally helps to further minimize the misclassification. The marker panel RF, IL-6 plus pro-MMP-1 has a total error of 10 slightly below 0.148.

Table 4:  
Classification results on the training set of patients diagnosed with RA versus controls incl. OA

No of Markers	marker or marker panel	Method (RDA)	Cross validation (10 fold)		
			TOTAL ERROR	Sensitivity	Specificity
1	log total RF	$\lambda = 0, \gamma = 0$	0.18	68.2%	95.6%
2	log total RF, log IL-6	$\lambda = 0, \gamma = 0.5$	0.15	74.6%	95.1%
3	log total RF, log IL-6, log pro-MMP-1	$\lambda = 0, \gamma = 0.25$	0.15	75.7%	95.1%

15 Most critical for the approach chosen in this study is the question if it has a general applicability. To test this, the marker panel identified in the training set was validated with an independent test set. As the skilled artisan will understand, the results of the training and the test set may differ slightly because both sets were truly independent. Table 5 gives the classification results using the same single marker RF  
20 or marker panels as in Table 4. As in the training set the combination of RF with IL-6, and optionally with pro-MMP-1, reduces the total error of the classification. The results presented in Table 4 and 5 clearly show that the combination of RF, IL-6 and optionally at least one additional marker significantly improves the diagnosis of RA, especially as compared to total RF.

- 24 -

Table 5:  
 Classification results on the test set of patients diagnosed with RA versus controls  
 including patients with OA

No of Markers	marker or marker panel	Method (RDA)	Classification of Test Set		
			TOTAL ERROR	Sensitivity	Specificity
1	log total RF	$\lambda = 0, \gamma = 0$	0.19	66.9%	94.6%
2	log total RF, log IL-6	$\lambda = 0, \gamma = 0.5$	0.14	76.9%	95.3%
3	log total RF, log IL-6, log pro-MMP-1	$\lambda = 0, \gamma = 0.25$	0.14	77.7%	95.3%

5 The ROC-curves for the markers and marker combinations, respectively, of Table 5 are shown in Figures 1 to 3.

List of References

Al-Dehaimi, A.W., et al., *Clin. Chem.* 45 (1999) 676-681

Arnett, F. C., et al., *Arthritis Rheum.* 31 (1988) 315-324

5 Ballara, S., *Arthritis Rheum.* 44 (2001) 2055-2064

Bartfeld, H., *Ann. NY Acad. Sci.* 168 (1969) 30-40

Bas, S., et al., *Ann. Rheum. Dis.* 61 (2002) 505-510

Billinghurst, R. C., et al., *J. Clin. Invest.* 99 (1997) 1534-45

Bonde, M., et al., *Clin. Chem.* 40 (1994) 2022-2025

10 Brenchley, P. E. C., *Clin. Exp. Immunol.* 121 (2000) 426-429

Breiman, L., Friedman, J. H., Olshen, R. A. & Stone, C. J. (1984) *Classification and regression trees*, California: Wadsworth

Breiman, L., *Random Forests, Machine Learning*, 45 (2001) 5-32

Burmeister, G., and Gallacchi, G., *Inflammopharmacology* 3 (1995) 221-230

15 Chabas, D., et al., *Science* 294 (2001) 1731-1735

Chambers, R. E., et al., *Ann. Rheum. Dis.* 42 (1983) 665-667

Duda, R. O., Hart, P. E., Stork, D. G., *Pattern Classification*, Wiley Interscience, 2nd Edition (2001)

Foell, D., et al., *Rheumatology* 42 (2003) 1383-1389

20 Friedman, J. H., *Regularized Discriminant Analysis*, *J. of the American Statistical Association*, Vol. 84 (1989) 165-175

Gineyts, E., et al., *Rheumatology* 40 (2001) 315-323

Gundberg, C. M., et al., *J. Clin. Ligand Assay* 21 (1998) 128-138

Hastie, Trevor, Tibshirani, Robert, Friedman, Jerome, *The Elements of Statistical*

25 *Learning*, Springer Series in Statistics, 2001

Hochberg, M. C., et al., *Arthritis Rheum.* 35 (1992) 498-502

Horneff, G., et al., *Clin. Exp. Immunol.* 91 (1993) 207-213

Ishiguro, N., et al., *Arthritis Rheum.* 44 (2001) 2503-2511

Johansen, J. S., et al., *Scand. J. Rheumatol.* 30 (2001) 297-304

30 Jorgensen, C., et al., *Clin. Exp. Rheum.* 14 (1996) 301-304

Kaufmann, J., et al., *Rheumatology* 42 (2003) 314-320

Kellgren, J. H., and Lawrence, J. S., *Ann. Rheum. Dis.* 16 (1957) 494-502

Knott, L., and Bailey, A. J., *Bone* 22 (1998) 181-187

Lee, S. S., et al., *Clin. Exp. Rheumatology* 19 (2001) 321-324

35 Lorenzo, P., et al., *J. Biol. Chem.* 273 (1998) 23463-23468

- 26 -

McLachlan, G. J., *Discriminant Analysis and Statistical Pattern Recognition*, Wiley  
Series in probability and mathematical statistics, 1992

Methods in Enzymology, eds. S.P. Colowick, N.O. Caplan and S.P., Academic Press,  
dealing with immunological detection methods, various volumes  
5 especially volumes 70, 73, 74, 84, 92 and 121.

Moore, T. L., and Dorner, R. N., *Clin Biochem.* 26 (1993) 75-84

Mozes, G. et al., *J. Trauma* 29 (1989) 71-74

Müller-Ladner, U., et al., *Rheumatology* 38 (1999) 148-154

Pepe, M. S., *The Statistical Evaluation of Medical Tests for Classification and  
10 Prediction*, Oxford Statistical Science Series, 28 (2003)

Petrow, P. K., et al., *Arthritis Rheum.* 43 (2000) 1597-1605

Ruczinski, I., Kooperberg, C., LeBlanc, M., *Logic regression,  
J. of Computational and Graphical Statistics*, 12 (2003) 475-511

Sawai, T., and Uzuki, M., *Connective Tissue* 33 (2001) 253-259

15 Saxne, T., and Heinegard, D., *Br. J. Rheumatol.* 31 (1992) 583-591

Saxne, T., et al., *Arthritis. Rheum.* 38 (1995) 82-90

Suzuki, F., *Connect. Tissue Res.* 35 (1996) 303-307

Swedler, W., et al., *J. Rheumatol* 24 (1997) 1037-1044

Tijssen, P., In: *Practice and theory of enzyme immunoassays*, eds. R. H. Burdon and  
20 v.P.H. Knippenberg, Elsevier, Amsterdam (1990) 221-278

Van der Heijde, D. M., *Br J. Rheumatol.* 34 (1995) 74-78


Waaler, E., *Acta Pathol. Microbiol. Scand.* 17 (1940) 172-188


Zweig, M. H., and Campbell, G., *Clin. Chem.* 39 (1993) 561-577

**CLAIMS:**

1. A method for assessing the absence or presence of rheumatoid arthritis *in vitro* by biochemical markers, comprising:
  - a) measuring in a sample the concentration of at least rheumatoid factor (RF) and interleukin-6 (IL-6),
  - b) mathematically combining the values measured for RF and IL-6 using Discriminant analysis, Kernel Methods, Nonparametric Methods, Partial Least Squares, Tree-Based Methods, Generalized Linear Models, Principal Components based Methods, Generalized Additive Models, Fuzzy Logic based Methods, Neural Networks or Genetic Algorithms based Methods, and
  - c) correlating the combined value from (b) to the absence or presence of rheumatoid arthritis.
2. The method according to claim 1, further comprising measurement of at least one additional marker consisting of C-reactive protein (CRP), serum amyloid A (SAA), S100 osteopontin, pro-matrix metalloprotease 1 (pro-MMP-1), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, soluble CD14 (sCD14), an angiogenesis marker or a product of bone, cartilage or synovium metabolism, and mathematically combining the value measured for the at least one additional marker in step b).
3. The method according to claim 2, wherein said additional marker is pro-MMP-1.
4. A use of mathematically combined measured values of a marker panel comprising at least rheumatoid factor (RF) and interleukin-6 in the diagnosis of rheumatoid arthritis (RA).
5. The use according to claim 4, wherein the marker panel comprises at least one additional marker consisting of C-reactive protein (CRP), serum amyloid A (SAA), S100 osteopontin, pro-matrix metalloprotease 1 (pro-MMP-1), matrix metalloprotease 1 (MMP-1), matrix metalloprotease 3 (MMP-3), hyaluronic acid, soluble CD14 (sCD14), an angiogenesis marker or a product of bone, cartilage or synovium metabolism.

6. A use of mathematically combined measured values of a marker panel comprising at least rheumatoid factor (RF), interleukin-6 and pro-MMP-1 marker in the diagnosis of rheumatoid arthritis (RA).
7. A kit for performing the method according to claim 1 comprising reagents required to specifically measure rheumatoid factor (RF) and interleukin-6, respectively.
8. The kit of claim 7 additionally comprising an auxiliary reagent for measuring RF or interleukin-6.

**Fig. 1**

**Fig. 2**

**Fig. 3**